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ABSTRACT 
Purpose: A randomized controlled study was done to evaluate the efficacy of the self-reinforced 
polyglycolic acid spiral stent compared to a suprapubic catheter, and combined suprapubic and 
indwelling catheters in the prevention of urinary retention after visual laser ablation of the 
prostate. 
Materials and Methods: We studied 72 men with benign prostatic hyperplasia who underwent 
placement of a suprapubic catheter and visual laser ablation of the prostate. In 27 men in group 
1 the self-reinforced polyglycolic acid spiral stent was inserted into the prostatic urethra after 
visual laser ablation of the prostate, while 23 in group 2 received no other devices. In 22 men in 
group 3 an indwelling catheter was left in situ for an average of 6.5 days. 
Results: Voiding began 1 or 2 days postoperatively in 20 of 27 patients (median 1 day) in group 
1, and 8 of 23 (median 6 days) in group 2. In 16 of 22 men in group 3 voiding began 1 or 2 days 
(median 6) after removal of the indwelling catheter. Improvements in patient weighted symptom 
score, mean peak urinary flow rate and post-void residual volume were significant (p <0.001) at 
6 months of followup in all groups. The overall infection rate was 30%. 
Conclusions: The self-reinforced polyglycolic acid spiral stent is superior to the suprapubic 
catheter alone, and to combined indwelling and suprapubic catheters for the treatment of 
postoperative urinary retention after laser therapy, offering possibilities for shorter catheteriza- 
tion time. 
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Benign prostatic hyperplasia (BPH) is a common phenom- 
enon in aging men. For more than 60 years transurethral 
electroresection of the prostate has been the gold standard 
for treatment of bladder outlet obstruction secondary to BPH. 
However, this procedure requires much experience and the 
complication rate has remained relatively constant during 
the last 30 years.' The American Urological Association CO- 
operative study has shown an 18% immediate postoperative 
morbidity rate with a perioperative mortality rate of 0.2%.2 
For these reasons there has been interest in development of 
minimally invasive approaches to treat BPH. 
Visual laser ablation of the prostate, an alternative treat- 
ment of BPH, was first described for clinical use in Australia 
in 1992.3 Therapy is based on photothermal coagulation of 
the prostate tissue with a neodymium:YAG laser and a right- 
angle, side firing, free beam delivery system. However, sev- 
eral problems are associated with visual laser ablation of the 
prostate, including postoperative urinary retention due to 
burn edema and the need for prolonged urinary catheteriza- 
tion in up to 38% of  patient^.^ 
In 1980 Fabian introduced a urological spiral to keep the 
prostatic lobes from compressing the urethra, thus allowing 
for spontaneous voiding.5 Others have reported good results 
with similar spirals for transient or definitive therapy of 
prostatic obstruction.6- 7 In the early 1990s ultrahigh 
strength, self-reinforced, biodegradable, polymeric eompos- 
ites were developed for tissue management.8 Self-reinforced, 
Accepted for publication July 26, 1996. 
poly-1-lactide spirals showed good biocompatibility in the an- 
terior urethra.9 Self-reinforced polyglycolic acid and polylac- 
tic acid rods have also been used for 10 years for fixation of 
bone fractures with favorable results."J In 1995 we intro- 
duced a biodegradable self-reinforced polyglycolic acid spiral 
stent that prevented urinary retention after visual laser ab- 
lation of the prostate.ll The hypothesis for the present study 
was that suprapubic or indwelling catheterization time after 
visual laser ablationpf the prostate can be shortened with 
use of a biodegradable spiral stent. A randomized controlled 
study was done to evaluate the efficacy of the self-reinforced 
polyglycolic acid spiral stent compared to a suprapubic cath- 
eter, and combined suprapubic and indwelling catheters for 
prevention of urinary retention after visual laser ablation of 
the prostate. 
MATERIALS AND METHODS 
Spiral stent. The self-reinforced polyglycolic acid spiral 
stent used was manufactured by extrusion and die drawing,8 
with a wire diameter of 1.1 mm. and a draw ratio of 4 (see 
figure). In configuration, the device resembled the stent de- 
scribed by Fabian.6 The spiral was 8 mm. in diameter and, in 
the prostatic portion, 45 mm. long. The wire tended to 
straighten so that during 14 days the outer diameter in- 
creased by 64%. The catheter was composed of biocompatible 
material that degraded in vitro into glycolic acid, mainly by 
hydrolysis.12 Some enzymes in vivo as well as elevated in 
vitm temperature have been found to accelerate degradation. 
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Spiral stent of 1.1 rnm. self-reinforced polyglycol!c acid wire with 
8 mm. outer diameter, 45 mm. diameter of prostatlc portion and 75 
mm. total length. 
The end products of the degradation are water and carbon 
dioxide.13. l4 The mechanical properties and degradation time 
depend on the degree of polymerization, the internal ar- 
rangement of the material components, site of implantation 
and shape of the implant. The spirals were sterilized with 
ethylene oxide. 
Patients. A total of 72 patients 52 to 83 years old (mean age 
68.5) with symptomatic BPH entered the study. Patients 
with malignancy of the bladder or prostate, chronic bacterial 
prostatitis, urethral stricture or previous surgery of the pros- 
tate, as well as therapy with cholinergic or anticholinergic 
drugs, or finasteride were excluded from the study. Peak 
urinary flow rate was less than 15 ml. per second with a 
voided volume of more than 150 ml. 
The patients were randomized into 3 groups: group 1-27 
in whom a self-reinforced polyglycolic acid spiral stent was 
inserted after laser therapy, group 2-23 who received only 
the suprapubic catheter after laser therapy and group 3-22 
in whom a 20 Ch. silicone indwelling catheter was inserted in 
addition to a suprapubic catheter. All patients received a 12 
Ch. suprapubic balloon catheter at cystoscopy before laser 
therapy, which was removed when the patient was able to 
void. Three patients in group 1, 2 in group 2 and 1 in group 
3 had urinary retention. Ultrasound guided biopsies were 
obtained if prostate specific antigen was greater than 4.0 
ng.lml., or digital rectal examination or transrectal ultra- 
sound indicated abnormality. Mean prostatic weight was 46 
gm. (range 19 to 90) in group 1, 40 gm. (range 17 to 91) in 
group 2 and 41 gm. (range 16 to 77) in group 3. 
Visual laser ablation of the prostate and application of the 
self-reinforced polyglycolic acid spiral stent. A standard tech- 
nique for visual laser ablation of the prostate was used with 
a side firing fiber. Standard neodymium:YAG generators 
were used to deliver photothermal energy. The power setting 
was 40 to 50 watts for 90 seconds for the lateral lobes and 45 
seconds for the median lobe. Laser energy was delivered to 
the lateral lobes in 4 quadrants circumferentially at  the 2,4,  
8 and 10 o’clock positions in 2 planes when the prostatic 
urethra was longer than 2.5 cm. In addition, a slow painting 
technique was used for additional lasing to achieve total 
bleaching of the surface of the lateral lobes. After removal of 
the laser fiber a 5 Ch. ureteral catheter was inserted through 
the cystoscope into the bladder, and the cystoscope was re- 
moved. With the tip of the cystoscope a self-reinforced poly- 
glycolic acid spiral stent was pushed into the prostatic ure- 
thra along the ureteral catheter. The correct location of the 
stent was verified endoscopically. The patients were allowed 
to void immediately and voiding ability was recorded. The 
suprapubic catheter was removed when the patient was able 
to void freely, and the patient was discharged from the hos- 
pital. 
Followup. Followup studies consisted of uroflowmetry; ul- 
trasonic estimation of post-void residual urine; analysis of 
serum creatinine, c-reactive protein and urine culture; a pa- 
tient weighted symptom score questionnaire (DAN-PSS-l, 
including questions addressing sexual problems),15 and ure- 
throcystoscopy. The studies were performed preoperatively, 
and a t  4 weeks, and 3 and 6 months after visual laser abla- 
tion of the prostate. Transrectal ultrasound was also per- 
formed a t  6 months. 
Statistics. The paired Student t test was used to evaluate 
differences among the time points. The chi-square test was 
used to evaluate the beginning of voiding. A value of p ~0.05 
was considered statistically significant. 
RESULTS 
All but 1 patient completed 6 months of followup. The 
mean dose of laser energy used was 957 (range 367 to 2,188), 
950 (range 573 to 2,074) and 983 (range 554 to 2,270) J./gm. 
in groups 1 ,2  and 3, respectively. Of the 27 patients in group 
1,20 voided freely on postoperative day 1 or 2 compared to 8 
of 23 in group 2 (p <0.001). The mean prostatic size was 53 
gm. (range 26 to 83) in 7 patients with delayed voiding in 
group 1, of whom 2 had urinary retention preoperatively and 
at 1 month of followup. Mean prostatic size did not differ 
significantly (p <0.34) from that of patients with free post- 
operative voiding. In group 3 the indwelling catheter was 
removed at an average of 6.5 days, after which 16 of 22 
patients were able to void within 2 days. 
In group 1 bleeding from the prostate during laser therapy 
caused blood clots postoperatively and delayed voiding in 1 
patient. In 2 patients the spiral stent was pushed proximally 
because of placement too distally: 1 had urinary leakage and 
1 had urinary retention. One patient had a thin, membrane- 
like stricture at the external sphincter area at  1 month of 
followup, which was treated with internal urethrotomy and 
no further strictures occurred. In 1 patient a suprapubic 
catheter was reinserted for 7 days because of preperitoneal 
urine leakage after removal of the initial catheter. Four pa- 
tients in group 4 who had postoperative urinary retention 
(range 4 to 29 days) were treated after the beginning of 
voiding and removal of the suprapubic catheter. Transure- 
thral incision of the prostate was performed 3 months post- 
operatively in 1 of these patients because of stricture of the 
bladder neck. 
In group 3 there were 2 cases of urinary retention at 10 
days and 2 months postoperatively, which also included hem- 
orrhage requiring bladder irrigation. Also, 1 patient had 
stricture at the external sphincter area 3 months postopera- 
tively, which was treated by intermittent urethrotomy and 
self-dilation. 
Peak urinary flow rates increased highly significantly dur- 
ing the 6 months of followup (p <0.001, see table) in all  
groups, whereas such improvement was already significant 
at  1 month in groups 1 and 2 but not in group 3. At 6 months 
peak flow urinary rates were significantly higher in groups 1 
and 2 than 3 (p C0.05). The difference between peak urinary 
flow rates in groups 1 and 2 was not significant a t  6 months. 
Mean residual urine decreased from 164 to 40 (p <0.01), 139 
to 40 (p <0.001) and 138 to 40 (p ~0.01) ml. in groups 1 to 3, 
respectively, at 6 months. The patient weighted prostatic 
symptom score decreased highly significantly at 6 months of 
followup (p <0.001) in every group. There were no significant 
differences in symptom scores between the groups at  6 
months. There was no significant change in sexual symptom 
score in any group. 
Group 1 patients stated that voiding was unobstructed 
during the first 3 weeks postoperatively. Thereafter, some 
patients experienced diminished stream force and increased 
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Peak urinary flour rates and patient weighted symptom scores ---- 
Mean (range) 
Group 1 Group 2 Group 3 
peak now rate (ml./sec.): 
Preop. 8.4 15.0-15.4) 7.5 (3.2-14.7) 8.4 (3.S15.6) 
postnp.: 
I Mo. 10.2(2.9-21.1)* 11.1 (2.2-48.4)* 9.5(3.%22.9) 
3 Mos. 15.3 (8.1-31.2)t 14.6 (5.6-26.7)t 11.8 (3.5-27) 
6 Mos. 15.8 (5.8-24.0)t 16.4 ( 4 . ~ 8 . o ) t  11.3 (5.4-20.3)* 
Symptom score 
(DAN-PSS-1): 
Preop. 23.3 (4-54) 22.1 (4-55) 18.4 ( 5 4 9 )  
Postop: 
1 Mo. 15.3 (1-56)* 13.3 (0-47) 15.9 (036)* 
3 Mas. 8.8 (0-33)t 10.6 (C!-28)* 7.7 (0-19)* 
6 Mos. 4.7 (C25)t  4.4 (0-16)t 6.0 (033)t 
Significant difference from preoperative value, p <0.05. 
t Significant difference from preoperative value, p <0.001. 
obstructive symptoms for several weeks. This increase in 
symptoms fits well with the degradation time of the self- 
reinforced polyglycolic acid spiral stent as evaluated by ure- 
throscopy. At 4 weeks patients still had some spiral stent 
fragments in the posterior urethra. No foreign bodies or 
urinary stones were noted in the bladder at 3 or 6 months. 
The entire prostatic urethra was lined with necrotic tissue 4 
weeks postoperatively in all patients. At 3 months half of the 
lased prostatic surface was still covered with necrotic tissue, 
and a third of the patients still had a few small necrotic areas 
in the prostatic urethra a t  6 months after visual laser abla- 
tion of the prostate. 
No blood transfusions were required. Urine culture was 
positive 4 weeks postoperatively in 6 patients in group 1,7 in 
group 2 and 7 in group 3, and remained positive at 3 months 
in 2, 2 and 3, respectively. Postoperative infections occurred 
during followup in 7 of 27 patients (26%) in group 1, 8 of 23 
(35%) in group 2 and 8 of 22 (36%) in group 3. The overall 
infection rate was 30%. The infection rates among the treat- 
ment groups were not significantly different. However, all 
urinary tract infections occurred in patients with more than 
4 days of suprapubic catheterization. 
DISCUSSION 
Laser therapy induces a high temperature in prostatic 
tissue causing acute tissue swelling due to burn edema, 
which tends to obstruct the prostatic urethra and cause tran- 
sient urinary retention. This retention is conventionally pre- 
vented by use of an indwelling or suprapubic catheter. How- 
ever, there is no consensus as to when the catheter should be 
removed. Intervals of 24 hours to 7 days have been recom- 
rnended.4.16.17 Prolonged indwelling or suprapubic catheter- 
ization aRer visual laser ablation of the prostate is inconve- 
nient for the patient, and the suprapubic and indwelling 
catheters provide a route for bacterial infection into the blad- 
der.18 Bacterial contamination of the necrotic prostatic tissue 
may even lead to prolonged urinary infection. After laser 
prostatectomy infection rates of up to 30% have been report- 
ed. l9.20 In our study the incidence of postoperative infections 
was significantly lower during the short 1 to 2-day catheter- 
ization period, which suggests that infections associated with 
visual laser ablation of the prostate are due to catheter 
contamination and migrating infection. With the spiral stent 
we can decrease effectively the incidences of postoperative 
urinary retention and infection, both of which are common 
complications of laser therapy. 
In 1995 T&a et al introduced a new biodegradable self- 
reinforced-polyglycolic acid spiral stent, with which urinary 
retention after visual laser ablation of the DrOState  can be 
most of our patients did not notice softened debris in the 
urine. Any polymer fragments remaining in the bladder will 
degrade completely within a few weeks without stone forma- 
tion. In previous experimental studies we have shown that 
biodegradable materials are biocompatible in the anterior 
urethra. Spirals made of self-reinforced polylactic acid in- 
duced less incrustation and inflammation in the urethra 
than did stainless steel spirals.9 
Some of our patients in the spiral stent group noticed that 
voiding became more obstructed at  3 to 4 weeks postopera- 
tively, which was probably due to the degradation and 
sloughing of the spiral stent. At that time edema and necrotic 
debris still obstructed the prostatic urethra. However, the 
obstructive symptoms decreased to a similar level a t  4 weeks 
of followup in all patients. This transient voiding problem 
might be avoided with use of a spiral stent with a longer 
degradation time of up to several months, achieved by select- 
ing more slowly degrading molecules. 
Thus, the outcome of visual laser ablation of the prostate in 
our study was in line with the results reported by oth- 
em4, l6. l7 Overall, the decrease in voiding symptoms was 
highly significant. The patient weighted symptom score was 
useful in our study, since it also included a bother score and, 
therefore, is considered to provide a more reliable estimate of 
symptoms than do other scoring systems.16 Mean laser en- 
ergy in our study was 963 J./gm., compared to 656 JJgm. in 
our previous study,11 which we believe indicates improved 
overall results. Energy levels of 1,000 to 2,000 J./gm. or more 
have been recommended.21 There was no late urinary reten- 
tion in the spiral stent group during followup. Despite the 
greater energy dose, much adenoma remained on cystoscopic 
examination in many patients a t  6 months. Improvement in 
peak urinary flow rates was greater in groups 1 and 2 than in 
group 3. However, there were no significant differences in 
baseline parameters, laser therapy, infection rate or addi- 
tional procedures. 
CONCLUSIONS 
Although visual laser ablation of the prostate offers some 
advantages over transurethral electroresection of the pms- 
tate, including a faster and safer procedure as well as shorter 
hospitalization, the burn-like edema produced after lasing 
means that a catheter or other device is required to prevent 
urinary retention. The biodegradable self-reinforced polygly- 
colic acid spiral stent is a novel method of preventing urinary 
retention after visual laser ablation of the prostate. Use of 
this device decreases the need for catheterization. The spiral 
stent has also been used with good results to prevent urinary 
retention after microwave therapy a t  a high energy setting.= 
The spiral stent might be effective in treatment modalities 
after other BPH therapies that might induce edema, such as 
transurethral needle ablation of the prostate, high intensity 
focused ultrasound, interstitial laser coagulation of the pms- 
tate and cryotherapy. Other indications for the spiral stent 
might be recurrent bladder neck strictures and temporary 
treatment of patients with urinary retention who are await- 
ing surgery. However, further controlled studies are needed 
to compare the spiral stent to other methods of preventing 
urinary retention. Spiral stents with a shorter expansion 
time, various degradation times and configurations are also 
issues of further interest. 
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